REGN FY 2023 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$81B

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$13.1B+7.8% YoY

Gross Profit

$10.9B82.9% margin

Operating Income

$4.3B33.2% margin

Net Income

$4.0B30.1% margin

EPS (Diluted)

$34.77

Cash Flow

Operating Cash Flow

$4.6B

Free Cash Flow

$3.7B

Stock-Based Comp.

$885M

Balance Sheet

Total Assets

$33.1B

Total Liabilities

$7.1B

Stockholders' Equity

$26.0B

Cash & Equivalents

$2.7B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$13.1B	$12.2B	+7.8%
Gross Profit	$10.9B	$10.5B	+3.9%
Operating Income	$4.3B	$5.4B	-19.3%
Net Income	$4.0B	$4.3B	-8.9%